Q2 2020 Astellas Pharma Inc Earnings Call Transcript
Good afternoon, ladies and gentlemen. Today, thank you very much for coming to our meeting for us to announce our second-quarter financial results. So let me go into my presentation without any further ado. Page 2 is a cautionary statement, as [already] explained, so let me skip. Page 3, this is the agenda for today in my presentation.
Page 4, this slide gives you an overview of the consolidated results on a core basis. Revenues increased to JPY650.5 billion, up 0.5% year-on-year. Core operating profits rose to JPY168 billion, up 8.9% year-on-year. Core profits were JPY135.9 billion, up 8.9% year-on-year. Core EPS rose by 12.8%.
Next page please. This slide shows the year-on-year revenue analysis. The top, JPY647.1 billion, and the four lines beneath. As you can see there, sales of major products increased year-on-year. XTANDI, XOSPATA, mirabegron, global products had increased sales and Evenity launched in March and new product in Japan contributed to increased sales.
On the other hand, in the United States
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
